NEWRON PHARMACEUT. EO-20 Market Cap ($231.08 Million)
Market Cap & Net Worth: NEWRON PHARMACEUT. EO-20 (NP5)
NEWRON PHARMACEUT. EO-20 market cap. NEWRON PHARMACEUT. EO-20 (F:NP5) has a market capitalization of $231.08 Million (€197.66 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #15809 globally and #1528 in its home market, demonstrating a 4.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NEWRON PHARMACEUT. EO-20's stock price €9.50 by its total outstanding shares 20805797 (20.81 Million). Also see how efficiently does NEWRON PHARMACEUT. EO-20 generate cash for how efficiently the company converts equity into cash flow.
NEWRON PHARMACEUT. EO-20 Market Cap History (2015–2026)
NEWRON PHARMACEUT. EO-20 market cap history from 2015 to 2026. Data shows change from $559.46 Million to $228.65 Million (-7.70% CAGR). Check NEWRON PHARMACEUT. EO-20 stock price for real-time trading data and today's change.
NEWRON PHARMACEUT. EO-20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NEWRON PHARMACEUT. EO-20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NEWRON PHARMACEUT. EO-20 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
33.89x
NEWRON PHARMACEUT. EO-20's market cap is 33.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $36.53 Million | $5.76 Million | -$14.90 Million | 6.34x | N/A |
| 2022 | $35.76 Million | $6.09 Million | -$17.49 Million | 5.87x | N/A |
| 2023 | $136.22 Million | $9.06 Million | -$16.22 Million | 15.04x | N/A |
| 2024 | $225.97 Million | $51.39 Million | $15.84 Million | 4.40x | 14.26x |
| 2025 | $648.24 Million | $19.13 Million | -$13.24 Million | 33.89x | N/A |
Competitor Companies of NP5 by Market Capitalization
Companies near NEWRON PHARMACEUT. EO-20 in the global market cap rankings as of November 4, 2026. Also see how large is NEWRON PHARMACEUT. EO-20's balance sheet for a full breakdown of the balance sheet.
Key companies related to NEWRON PHARMACEUT. EO-20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of NEWRON PHARMACEUT. EO-20 (2015–2026)
Market capitalization of NEWRON PHARMACEUT. EO-20 from 2015 to today. Between 2015 and today, NEWRON PHARMACEUT. EO-20's market cap moved from $559.46 Million to $ 228.65 Million, with a yearly change of -7.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €228.65 Million | -64.73% |
| 2025 | €648.24 Million | +186.87% |
| 2024 | €225.97 Million | +65.89% |
| 2023 | €136.22 Million | +280.95% |
| 2022 | €35.76 Million | -2.13% |
| 2021 | €36.53 Million | -21.44% |
| 2020 | €46.51 Million | -66.46% |
| 2019 | €138.65 Million | -75.22% |
| 2018 | €559.46 Million | 0.00% |
| 2017 | €559.46 Million | 0.00% |
| 2016 | €559.46 Million | 0.00% |
| 2015 | €559.46 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of NEWRON PHARMACEUT. EO-20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $231.08 Million USD |
| MoneyControl | $231.08 Million USD |
| MarketWatch | $231.08 Million USD |
| marketcap.company | $231.08 Million USD |
| Reuters | $231.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more